摘要
目的:探讨HBV-DNA载量测定的临床意义及其与HBV-M、拉米夫定治疗的相关性。方法:采用酶联免疫吸附试验和荧光定量聚合酶链反应技术对280例乙肝患者HBV-M和HBV-DNA载量进行检测;同时动态检测32例乙肝患者48周拉米夫定治疗期间血清HBV-M和HBV-DNA载量变化。结果:HBeAg(+)组患者血清HBV-DNA载量显著高于HBeAg(-)组(P<0.01);不同临床类型急性肝炎组HBV-DNA载量与其它组比较(P<0.05);其它各组HBV-DNA载量之间比较(P>0.05);拉米夫定治疗12周、24周、48周后HBV-DNA载量迅速下降,与治疗前比较(P<0.001);HBV-DNA载量下降明显较HBeAg血清学转换发生早。结论:HBeAg是反映HBV-DNA复制的重要指标;HBV-DNA载量测定是反映HBV复制和判断药物疗效的最直接、可靠的指标。
Objective:To explore the Clinical significance of quantitative detection of hepatitis B virus DNA and investigate the correlation between HBV-DNA quantity and HBV serological marker,lamivudine therapy, respectively.Methods:Use ELISA and fluorescent quanting PCR( FQ-PCR ) to detect 280 serum samples with HBV infection the HBV marker and quantity of HBV-DNA, in addition to 32 patients with HBV infection who were treated with lamivudine and followed with the measurement mentioned above. Results:The contents of HBV DNA copies had a significant difference between HBeAg (+)/anti-HBe (-) group(P<0.01);among the infected patients with various liver impairment the contents of HBV-DNA in acute hepatitis was significantly higher than others(P<0.05)and no difference was found among other liver impairments; obvious reduction of HBV-DNA occurred in patients receiving lamivudine treat and the level of HBV-DNA was significantly lower during lamivudine therapy; the reduction of HBV-DNA was earlier than HBeAg negative reversion. Conclusions:HBeAg is an important index for HBV-DNA duplication; quantitative detection HBV-DNA is a direct, reliably index.
出处
《中国交通医学杂志》
2005年第3期218-220,共3页
Chinese Medical JOurnal of Communications
